Program Description
Triple-negative breast cancer (TNBC) is an aggressive, high-grade tumor subtype that is typically diagnosed in women younger than 40 years and leads to higher mortality rates compared with other tumor types. Several disparities, including differences in cancer incidence, mortality and survivorship, and disease-related burden, are associated with TNBC among women of different racial and ethnic groups. Biological, socioeconomic, and geographic social determinants of health have a role in determining the underlying cause of these disparities, emphasizing the need for a holistic approach to analyzing TNBC risk. In addition to these disparities, there are several contributors to treatment inequities for women with TNBC belonging to underserved populations. It is important for members of the multidisciplinary oncology team to recognize the factors that contribute to differences in the development, presentation, and outcomes among women with TNBC and implement appropriate measures to reduce the barriers and inequities experienced by some patients. The oncology health care team should also be educated in culturally competent and responsive care to improve quality of care, communication, and support for cultural minorities seeking treatment for TNBC to best address individual patient needs. The multidisciplinary panelists will discuss potential solutions that can proactively mitigate treatment disparities for patients with TNBC.
Target audience: Health-system, managed care, oncology, retail, and specialty pharmacists
Type of activity: Application
Time to complete activity: 1.5 hours
Release date: November 9, 2022
Expiration date: November 9, 2023
Fee: Free
Educational Objectives
- Explore the ways in which both biological and non-biological factors contribute to disparities in triple-negative breast cancer (TNBC)
- Correlate biological and non-biological disparities with their impact on mortality, quality of life, and survivorship for patients with TNBC
- Apply culturally responsive strategies into practice to improve care equity among patients with TNBC
Onye J. Ononogbu, PharmD, BCOP
Research Assistant Professor
Department of Pharmacy Practice and Translational Research
University of Houston College of Pharmacy
Hematology/Oncology Clinical Pharmacy Specialist
Harris Health System
Co-founder & Chief Program Officer
Pharmacy Initiative Leaders, Inc
Margaret Quinn Rosenzweig, PhD, FNP-BC, AOCNP, FAAN
Distinguished Service Professor of Nursing
Professor of Medicine
University of Pittsburgh
Pittsburgh, Pennsylvania
Ana Maria Lopez, MD, MPH, MACP, FRCP
Professor and Vice Chair, Medical Oncology, Sidney Kimmel Medical College
Director, Integrative Oncology
Medical Director, Medical Oncology and Chief of Cancer Services, Jefferson Health New Jersey,
Sidney Kimmel Cancer Center, NCI Designated
Thomas Jefferson University
President-Emeritus
American College of Physicians
Philadelphia, Pennsylvania
Susan Fugett, MSW, LISW-S, OSW-C, CSW-G
Clinical Oncology Social Worker- Ambulatory Lead
Patient Care Resource Manager and Social Work Department
The Ohio State University Wexner Medical Center
Columbus, Ohio
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-553-H01-P. The activity is available for CE credit through November 9, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Onye J. Ononogbu, PharmD, BCOP; Ana Maria Lopez, MD, MPH, MACP, FRCP; Susan Fugett, MSW, LISW-S, OSW-C, CSW-G; and Margaret Quinn Rosenzweig, PhD, FNP-BC, AOCNP, FAAN
Medical Writer
Jane de Lartigue, PhD
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here